NERV — Minerva Neurosciences Cashflow Statement
0.000.00%
- $11.89m
- -$9.47m
- 24
- 42
- 35
- 25
Annual cashflow statement for Minerva Neurosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 1.94 | -49.9 | -32.1 | -30 | 1.44 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 9.78 | 26.8 | 11.5 | 10.3 | -20.7 |
Other Non-Cash Items | |||||
Changes in Working Capital | -45.6 | 0.259 | -4.06 | 4.94 | -0.321 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -33.8 | -24.6 | -24.6 | -14.8 | -19.6 |
Capital Expenditures | — | — | -0.016 | 0 | — |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 24.5 | 0 | — | — | 0 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 24.5 | 0 | -0.016 | 0 | 0 |
Financing Cash Flow Items | -0.456 | 60 | 0 | -0.396 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 13.2 | 60 | -0 | 19.6 | — |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 3.94 | 35.4 | -24.7 | 4.82 | -19.6 |